Ardelyx, Inc. (ARDX) News
Filter ARDX News Items
ARDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARDX News Highlights
- For ARDX, its 30 day story count is now at 4.
- Over the past 15 days, the trend for ARDX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ARDX are DEC and VIEW.
Latest ARDX News From Around the Web
Below are the latest news stories about ARDELYX INC that investors may wish to consider to help them evaluate ARDX as an investment opportunity.
Ardelyx, Inc. Reports Employment Inducement GrantsWALTHAM, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on December 18, 2023, the compensation committee of the company’s board of directors granted sixteen new non-executive employees options to purchase an aggregate of 257,119 shares of the company’s common stock, and granted eighte |
There's Reason For Concern Over Ardelyx, Inc.'s (NASDAQ:ARDX) Massive 36% Price JumpDespite an already strong run, Ardelyx, Inc. ( NASDAQ:ARDX ) shares have been powering on, with a gain of 36% in the... |
3 Short-Squeeze Stocks Ready for a Year-End RallyThese are a few companies that have seen considerable gains this year that still have a large percentage of short interest. |
3 Stocks at the Forefront of Personalized Medicine TrendIn the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. These stocks highlight the trend of focusing on genetic and molecular characteristics, promising more effective healthcare solutions. This trend transcends medical innovation, marking its territory as a burgeoning economic powerhouse. Grand View Research forecasts the global personalized medicine market to rea |
7 Penny Stocks You’ll Regret Not Buying Soon: November 2023Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time. |
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare ConferenceWALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Ardelyx management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in New York City. To access the live webcast of Ardelyx's session, p |
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for HyperphosphatemiaArdelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%. |
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric HyperphosphatemiaWALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to XPHOZAH® (tenapanor) for the treatment of pediatric hyperphosphatemia. XPHOZAH is a single tablet taken twice daily that offers a first-in-class m |
Ardelyx (NASDAQ:ARDX) shareholders have earned a 226% return over the last yearUnfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality... |
Ardelyx Announces Departure of Board MemberWALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Geoffrey Block, MD, is stepping down from the Board of Directors after nearly five years of service. Dr. Block currently serves as the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Af |